{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:03:46Z","timestamp":1779001426795,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2018.08.085","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T08:56:55Z","timestamp":1543222615000},"page":"5796-5802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-5691","authenticated-orcid":false,"given":"Sonali","family":"Kochhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Bok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-3323","authenticated-orcid":false,"given":"Stephen J.","family":"Seligman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najwa","family":"Khuri-Bulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Klug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Laderoute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-519X","authenticated-orcid":false,"given":"Vidisha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.08.085_b0005","article-title":"Vaccination: the cornerstone of an efficient healthcare system","volume":"3","author":"R\u00e9my","year":"2015","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.vaccine.2012.10.103","article-title":"Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review","volume":"31","author":"Ozawa","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.085_b0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12865-015-0075-2","article-title":"New challenges in modern vaccinology","volume":"16","author":"Centlivre","year":"2015","journal-title":"BMC Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.08.085_b0020","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1039\/C6MB00268D","article-title":"New approaches and omics tools for mining of vaccine candidates against vector-borne diseases","volume":"12","author":"Kule\u0161","year":"2016","journal-title":"Mol Biosyst"},{"issue":"4","key":"10.1016\/j.vaccine.2018.08.085_b0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1590\/S0100-879X2005000400004","article-title":"Recombinant viruses as vaccines against viral diseases","volume":"38","author":"Souza","year":"2005","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.085_b0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7774\/cevr.2013.2.2.97","article-title":"Viral vectors for vaccine applications","volume":"2","author":"Choi","year":"2013","journal-title":"Clin Exp Vacc Res"},{"issue":"5","key":"10.1016\/j.vaccine.2018.08.085_b0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/COH.0b013e328363d389","article-title":"Development of replication-competent viral vectors for HIV vaccine delivery","volume":"8","author":"Parks","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"10.1016\/j.vaccine.2018.08.085_b0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-3024.2009.01141.x","article-title":"Viral vectors in malaria vaccine development","volume":"31","author":"Limbach","year":"2009","journal-title":"Parasite Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2018.08.085_b0045","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines","volume":"12","author":"de Vries","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2008.03.002","article-title":"SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is morepotent than one based on a replication-competent vector","volume":"376","author":"Kapadia","year":"2008","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0055","doi-asserted-by":"crossref","first-page":"e1006037","DOI":"10.1371\/journal.ppat.1006037","article-title":"Fighting Ebola: a window for vaccine re-evaluation?","volume":"13","author":"Chappell","year":"2017","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.vaccine.2018.08.085_b0060","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/erv.11.55","article-title":"Vaccination for hepatitis C virus: closing in on an evasive target","volume":"10","author":"Halliday","year":"2011","journal-title":"Expert Rev Vacc"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.085_b0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14760584.2014.878653","article-title":"Current concepts and progress in RSV vaccine development","volume":"13","author":"Guvenel","year":"2014","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.08.085_b0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijid.2016.10.018","article-title":"Novel approaches to tuberculosis vaccine development","volume":"56","author":"Kaufmann","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.085_b0075","unstructured":"<http:\/\/www.who.int\/immunization\/research\/meetings_workshops\/viral_vecto_meeting_oct13\/en\/> [accessed on 23 March 2018]."},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.085_b0080","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/21645515.2017.1389362","article-title":"Development of Middle East Respiratory Syndrome Coronavirus vaccines \u2013 advances and challenges","volume":"14","author":"Cho","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2018.08.085_b0085","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"27","key":"10.1016\/j.vaccine.2018.08.085_b0090","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","article-title":"A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections","volume":"36","author":"Chattopadhyay","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and multipathogen viral vector vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.08.085_b0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/rmv.360","article-title":"Alphavirus vectors and vaccination","volume":"12","author":"Rayner","year":"2002","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2018.08.085_b0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1743-422X-8-49","article-title":"Avipoxviruses: infection biology and their use as vaccine vectors","volume":"8","author":"Weli","year":"2011","journal-title":"Virol J"},{"issue":"7","key":"10.1016\/j.vaccine.2018.08.085_b0110","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.085_b0115","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00720-16","article-title":"Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses","volume":"91","author":"Crosby","year":"2017","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2018.08.085_b0120","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2018.08.085_b0125","unstructured":"Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. European Medicines Agency; 24 June 2010. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/08\/WC500095721.pdf> [accessed on 23 March 2018]."},{"issue":"51","key":"10.1016\/j.vaccine.2018.08.085_b0130","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0135","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and multipathogen viral vector vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2018.08.085_b0140","unstructured":"WHO informal consultation: development of viral vectored vaccines for HIV, malaria, tuberculosis and other indications; October 2013. <http:\/\/www.who.int\/immunization\/research\/meetings_workshops\/Oct2013_viral_vector_meeting_comments.pdf> [accessed on 23 March 2018]."},{"key":"10.1016\/j.vaccine.2018.08.085_b0145","unstructured":"WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors; December 2003. <http:\/\/www.who.int\/immunization\/research\/meetings_workshops\/viral_vectors_report_full.pdf> [accessed on 23 March 2018]."},{"key":"10.1016\/j.vaccine.2018.08.085_b0150","unstructured":"Methods for improving the safety and efficacy of vaccines against emerging virus pathogens. <https:\/\/www.fda.gov\/BiologicsBloodVaccines\/ScienceResearch\/BiologicsResearchAreas\/ucm127331.htm> [accessed on 23 Mar 2018]."},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton collaboration viral vector vaccines safety working group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.085_b0160","series-title":"Pharmacoepidemiology","article-title":"Special methodological issues in pharmacoepidemiology studies of vaccine safety","author":"Chen","year":"2005"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157488631001150407110435","article-title":"Communicating vaccine safety during the development and introduction of vaccines","volume":"10","author":"Kochhar","year":"2015","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.vaccine.2018.08.085_b0170","unstructured":"Miller Elaine R, Haber Penina, Hibbs Beth, Broder Karen. Surveillance for adverse events following immunization using the Vaccine Adverse Event Reporting System (VAERS). Manual for the surveillance of vaccine-preventable diseases, 5th ed.; 2011."},{"issue":"48Part A","key":"10.1016\/j.vaccine.2018.08.085_b0175","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2017.09.033","article-title":"Safety assessment of immunization in pregnancy","volume":"35","author":"Kochhar","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.vaccine.2012.07.024","article-title":"Biologically plausible and evidence-based risk intervals in immunization safety research","volume":"31","author":"Rowhani-Rahbar","year":"2012","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.08.085_b0185","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/pds.3638","article-title":"Risk of Guillain-Barr\u00e9 syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany","volume":"23","author":"Prestel","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0190","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12874-016-0225-0","article-title":"The use of relative incidence ratios in self-controlled case series studies: an overview","volume":"16","author":"Hawken","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.08.085_b0195","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1542\/peds.2010-1722I","article-title":"Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project","volume":"127","author":"Yih","year":"2011","journal-title":"Pediatrics"},{"issue":"48 Pt A","key":"10.1016\/j.vaccine.2018.08.085_b0200","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1016\/j.vaccine.2017.03.103","article-title":"Immunization in pregnancy clinical research in low- and middle-income countries \u2013 study design, regulatory and safety considerations","volume":"35","author":"Kochhar","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.085_b0205","unstructured":"World Health Organization report of the second meeting of the global vaccine safety initiative, 19\u201320 November 2013, New Delhi, India. <http:\/\/www.who.int\/vaccine_safety\/publications\/GVSI_meeting2_india_Nov_2013_report.pdf> [accessed on 26 March 2018]."},{"key":"10.1016\/j.vaccine.2018.08.085_b0210","unstructured":"FDA guidance for industry gene therapy clinical trials \u2013 observing subjects for delayed adverse events; November 2006. <https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/ucm078719.pdf> [accessed on Jan 25, 2018]."},{"key":"10.1016\/j.vaccine.2018.08.085_b0215","unstructured":"June 2015 FDA guidance on considerations for the design of early-phase clinical trials of cellular and gene therapy products. <https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM564952.pdf> [accessed on 12 April 2018]."},{"issue":"49","key":"10.1016\/j.vaccine.2018.08.085_b0220","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1016\/j.vaccine.2016.07.032","article-title":"Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women","volume":"34","author":"Jones","year":"2016","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.08.085_b0225","first-page":"1","article-title":"The Delphi technique: making sense of consensus","volume":"12","author":"Hsu","year":"2007","journal-title":"Pract Assess Res Eval"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.08.085_b0230","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.vaccine.2015.10.082","article-title":"White paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink","volume":"34","author":"Glanz","year":"2016","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2018.08.085_b0235","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.085_b0240","unstructured":"Statement on narcolepsy and vaccination. Global vaccine safety; April 2011. <http:\/\/www.who.int\/vaccine_safety\/committee\/topics\/influenza\/pandemic\/h1n1_safety_assessing\/narcolepsy_statement\/en\/> [accessed on 12 April 2018]."},{"issue":"6","key":"10.1016\/j.vaccine.2018.08.085_b0245","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.085_b0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11586620-000000000-00000","article-title":"Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance","volume":"34","author":"Borg","year":"2011","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.vaccine.2018.08.085_b0255","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.vaccine.2018.02.012","article-title":"Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000\u20132015","volume":"36","author":"Lei","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.08.085_b0260","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.08.085_b0265","unstructured":"Vaccine Safety Datalink. <https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html> [assessed on 6 March 2018]."},{"issue":"Suppl 10","key":"10.1016\/j.vaccine.2018.08.085_b0270","doi-asserted-by":"crossref","first-page":"K98","DOI":"10.1016\/j.vaccine.2013.04.088","article-title":"Post-licensure rapid immunization safety monitoring program (PRISM) data characterization","volume":"31","author":"Baker","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.085_b0275","unstructured":"Pilot of self-controlled tree-temporal scan analysis for gardasil vaccine. <https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/Methods\/Mini-Sentinel_PRISM_Pilot-Self-Controlled-Tree-Temporal-Scan-Analysis-Gardasil-Vaccine-Protocol_0.pdf> [accessed on 2 April 2018]."},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0280","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/pharmaceutics5010168","article-title":"Vaccine safety surveillance systems: critical elements and lessons learned in the development of the US Vaccine Safety Datalink\u2019s rapid cycle analysis capabilities","volume":"5","author":"Davis","year":"2013","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.vaccine.2018.08.085_b0285","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40264-014-0194-3","article-title":"A comparison of active adverse event surveillance systems worldwide","volume":"37","author":"Huang","year":"2014","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.vaccine.2018.08.085_b0290","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pds.3908","article-title":"Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System","volume":"25","author":"Yih","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2018.08.085_b0295","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kwy023","article-title":"Assessment of quadrivalent human papillomavirus vaccine safety using the self-controlled tree-temporal scan statistic signal-detection method in the Sentinel System","author":"Yih","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.08.085_b0300","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.3423","article-title":"Drug safety data mining with a tree-based scan statistic","volume":"22","author":"Kulldorff","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.085_b0305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1541-0420.00039","article-title":"A tree-based scan statistic for database disease surveillance","volume":"59","author":"Kulldorff","year":"2003","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2018.08.085_b0310","unstructured":"Case-control study in dos Santos Silva, I (ed.) Cancer epidemiology: principles and methods. Lyon (France): International Agency for Research on Cancer (IARC); 1999. <http:\/\/www.iarc.fr\/en\/publications\/pdfs-online\/epi\/cancerepi\/CancerEpi-9.pdf> [accessed on 26 March 2018] [chapter 9]."},{"issue":"11","key":"10.1016\/j.vaccine.2018.08.085_b0315","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1084\/jem.20140520","article-title":"Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies","volume":"211","author":"Casanova","year":"2014","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0320","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Vector Vaccines safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.08.085_b0325","doi-asserted-by":"crossref","first-page":"e1006682","DOI":"10.1371\/journal.ppat.1006682","article-title":"A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.085_b0330","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1186\/s12879-017-2838-2","article-title":"A comparison of the test-negative and the traditional case-control study designs for estimation of influenza vaccine effectiveness under nonrandom vaccination","volume":"17","author":"Shi","year":"2017","journal-title":"BMC Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T10:15:16Z","timestamp":1566641716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18312350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":66,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X18312350"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}